ArticleBlood advances2024
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML.
Carlos Jimenez-Chillon et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
20 papers cite it
this paperpooled ittrialcites it